ES Home Catalog Guides COAs Calculator
Tirzepatide
Home › Products › Fat Loss & Metabolism › Tirzepatide
← Back to catalog Fat Loss & MetabolismComing Soon

Tirzepatide

10 mg / vial
Dual agonistFDA-approvedWeight loss

Dual GIP/GLP-1 receptor agonist — FDA-approved molecule (Mounjaro/Zepbound) with record clinical efficacy in body-mass reduction and glycemic control studies (Phase III SURMOUNT-1, NEJM 2022), backed by years of clinical data.

  • Weight: Up to 22.5% body weight loss in 72 weeks (SURMOUNT-1 trial, NEJM 2022)
  • Glycemia: A1C reduction of 2.5%+ — comparable to basal insulin (SURPASS-1 to 5 trials)
  • Established profile: Approved by FDA, EMA, and global regulators — years of pharmacovigilance and tolerance data
$90 USD
💰 Buy multiple and save: 3+ vials −5% · 5+ −10%
📋 Technical datasheet · Compound specifications
CompoundTirzepatide
Origin🇺🇸 Lyophilized in USA (US-based facilities)
FormLyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formulaAvailable on request
Molecular weightAvailable on request
Purity≥99% by HPLC + mass spectrometry (Janoshik Analytical)
StorageLyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C, up to 28 days
Recommended solventBacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain2–8°C in transit · controlled thermal packaging
UseResearch Use Only (RUO). Not intended for human or veterinary use.

Typical values for this compound category. For batch-specific data, see the corresponding COA at /en/coa/.

🧪 Independent third-party analysis available — Janoshik Analytical (HPLC + MS).View all COAs →
This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.
Questions? Write us

Your Order

Your cart is empty